European Molecular Biology Laboratory

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

BioInnovation Institute welcomes innovative smartRNA project to Bio Studio program

Retrieved on: 
Thursday, March 14, 2024
Lykke, Epilepsy, EUR, KU Leuven, European Molecular Biology Laboratory, Haploinsufficiency, Genetics, Patient, Research, RNA, University of Washington, University, Messenger, Cancer, Laboratory, BII, Imperial College London, Student, EMBL, Monogenic, Aarhus University, University of Copenhagen, Intellectual property, Therapy, Molecular biology, DSM-IV codes, Disorder, Vaccine

Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.

Key Points: 
  • Thus, the aim of the smartRNA project in BII's Bio Studio program is to leverage this proprietary technology to develop treatments for currently untreatable disorders caused by haploinsufficiency or other monogenic diseases caused by reduced protein activity.
  • During the 3-year BII Bio Studio program, the objective of smartRNA is to deliver an in vitro proof-of-concept, a pseudo in vivo proof-of-principle, and in vitro benchmarking against established technologies.
  • Anja Mølhart Høg, Entrepreneur-in-Residence heading up the smartRNA project, added: "We are excited to welcome the smartRNA project to BII's Bio Studio program.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

Element Biosciences Announces Over 100 Commercial Orders of its AVITI System and Surpasses Q2 Sales Goals

Retrieved on: 
Wednesday, September 6, 2023
Metagenomics, University, EMBL, DNA sequencing, NGS, Research, Genome, Tavarua, Doctor of Philosophy, BioRxiv, Government, Creativity, Whole genome sequencing, Chemistry, Laboratory, FACMG, European, Element, RNA-Seq, Entrepreneurship, Massachusetts Institute of Technology, Health, SVP, European Molecular Biology Laboratory, Video game, Fine chemical, Antibiotics, Q2

/PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI™ System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced it has exceeded 100 orders of the AVITI System. With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks. The company has seen triple digit quarter-on-quarter growth since launch, and in Q2 reached an estimated 15 percent of the total sales of mid-throughput sequencing instruments, just one year after its first commercial shipments. Element has also signed distribution agreements with 11 distributors across the globe.

Key Points: 
  • With U.S. and international customers in 13 countries, Element has expanded its commercial team globally through direct sales and distribution networks.
  • "Today's milestone validates the market demand for truly differentiated solutions that help customers achieve more with sequencing, regardless of scale.
  • "As a data-driven company, we are committed to setting ambitious goals and consistently delivering data and outcomes that surpass expectations.
  • Over 40 percent of sales were multi-unit orders and Element also welcomed repeat customers adding capacity to their existing fleet of AVITI instruments.

27 to 29 June, Paris - World Leaders & Scientists to Discuss: Basic Research Can Pioneer New Approaches to Global Challenges

Retrieved on: 
Monday, June 26, 2023
UNESCO, Nobel Prize, Spanish National Center for Biotechnology, International, Civil service commission, Research fellow, Human Frontier Science Program, Liliane, French National Centre for Scientific Research, French Academy of Sciences, International Science Council, Sustainability, Korea, U.N, European, Auditorium, Institut Pasteur Korea, ARD International Music Competition, Sustainable development, Scientific method, Pasteur Institute, European Molecular Biology Laboratory, European Commission, Pharmaceutical industry, Environment

PARIS, June 26, 2023 /PRNewswire/ -- "Fundamental Life Science Meets Climate, Environment, and Sustainability," invites world leaders and scientists to forge new partnerships and propose systems-level approaches to solve global challenges. The events contribute toward the U.N. International Year of Basic Sciences for Sustainable Development.

Key Points: 
  • PARIS, June 26, 2023 /PRNewswire/ -- "Fundamental Life Science Meets Climate, Environment, and Sustainability," invites world leaders and scientists to forge new partnerships and propose systems-level approaches to solve global challenges.
  • High-Level Summit, 27 June, at French Academy of Sciences:
    International Scientific Symposium, 28 & 29 June, at Auditorium André and Liliane Bettencourt:
    English speakers: Rachael Bishop, [email protected] , +33 (0)7 81 87 62 21.
  • The Human Frontier Science Program was established in 1989 to advance international research and training at the frontier of life sciences.
  • With its collaborative research grants and postdoctoral fellowships, the program has awarded more than 4,500 fellowships involving more than 7,500 scientists from around the world.

27 to 29 June, Paris - World Leaders & Scientists to Discuss: Basic Research Can Pioneer New Approaches to Global Challenges

Retrieved on: 
Monday, June 26, 2023
UNESCO, Nobel Prize, Spanish National Center for Biotechnology, International, Civil service commission, Research fellow, Human Frontier Science Program, Liliane, French National Centre for Scientific Research, French Academy of Sciences, International Science Council, Sustainability, Korea, U.N, European, Auditorium, Institut Pasteur Korea, ARD International Music Competition, Sustainable development, Scientific method, Pasteur Institute, European Molecular Biology Laboratory, European Commission, Pharmaceutical industry, Environment

PARIS, June 26, 2023 /PRNewswire/ -- "Fundamental Life Science Meets Climate, Environment, and Sustainability," invites world leaders and scientists to forge new partnerships and propose systems-level approaches to solve global challenges. The events contribute toward the U.N. International Year of Basic Sciences for Sustainable Development.

Key Points: 
  • PARIS, June 26, 2023 /PRNewswire/ -- "Fundamental Life Science Meets Climate, Environment, and Sustainability," invites world leaders and scientists to forge new partnerships and propose systems-level approaches to solve global challenges.
  • High-Level Summit, 27 June, at French Academy of Sciences:
    International Scientific Symposium, 28 & 29 June, at Auditorium André and Liliane Bettencourt:
    English speakers: Rachael Bishop, [email protected] , +33 (0)7 81 87 62 21.
  • The Human Frontier Science Program was established in 1989 to advance international research and training at the frontier of life sciences.
  • With its collaborative research grants and postdoctoral fellowships, the program has awarded more than 4,500 fellowships involving more than 7,500 scientists from around the world.

Nucleai Expands Leadership Team and Scientific Advisory Board with Pharmaceutical Industry Experts

Retrieved on: 
Wednesday, May 24, 2023
Software, Research, Other Health, Pharmaceutical, Oncology, Technology, Artificial Intelligence, Health Technology, Clinical Trials, Science, Nanotechnology, Biotechnology, Health, Molecular biology, Drug development, University, Rockefeller University, Muller's morphs, BeiGene, Pathology, University of California, Davis, Cancer, Multimedia, Biomarker, Genentech, Bristol Myers Squibb, Weill Cornell Medicine, Traction, Phosphorus, Publication, Lilly, Translational medicine, European, Drug discovery, Merck, University of Valencia Science Park, European Molecular Biology Laboratory, Memorial Sloan Kettering Cancer Center, Pharmaceutical industry, Celgene

Nucleai, a leader in AI-powered spatial biology, today announced the two key appointments to its leadership team and scientific advisory board.

Key Points: 
  • Nucleai, a leader in AI-powered spatial biology, today announced the two key appointments to its leadership team and scientific advisory board.
  • Pharmaceutical industry veteran Oscar Puig, Ph.D. has been named the VP of Translational Medicine & Diagnostics at Nucleai, while Suzana Couto, the Head of Pathology at Neomorph Inc, has been appointed as a scientific advisor for the company.
  • “Their expertise and experience in top pharmaceutical companies perfectly complement Nucleai’s focus on serving the pharmaceutical industry.
  • As part of Nucleai’s scientific advisory board, she will help support the strategic direction and ongoing innovation in the company.

BioInnovation Institute welcomes innovative mycoprotein meat project into Bio Studio program

Retrieved on: 
Thursday, March 9, 2023
BII, Synthetic biology, CSO, Meat, University of Washington, Pi, Metabolic engineering, Engineering, European Molecular Biology Laboratory, Research, Principal investigator, Intellectual property, Animal, EUR, Imperial College London, Taste, Health, Food, FNC, University, MVP, EMBL, Institute of technology, UN, Technical University of Denmark Department of Mathematics, Consultant, Agriculture, Yarrowia

COPENHAGEN, Denmark, March 9, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces that it has accepted a new project into its Bio Studio program to develop an engineered mycoprotein meat alternative.

Key Points: 
  • COPENHAGEN, Denmark, March 9, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces that it has accepted a new project into its Bio Studio program to develop an engineered mycoprotein meat alternative.
  • BII's Bio Studio program supports world-leading entrepreneurial Principal Investigators (PIs) who want to translate their innovative research ideas into new solutions to the benefit of planetary and human health.
  • Thus, the goal of this project is to create an initial minimum viable product (MVP) of a holistically engineered mycoprotein meat alternative.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

BioInnovation Institute welcomes innovative mycoprotein meat project into Bio Studio program

Retrieved on: 
Thursday, March 9, 2023
BII, Synthetic biology, CSO, Meat, University of Washington, Pi, Metabolic engineering, Engineering, European Molecular Biology Laboratory, Research, Principal investigator, Intellectual property, Animal, EUR, Imperial College London, Taste, Health, Food, FNC, University, MVP, EMBL, Institute of technology, UN, Technical University of Denmark Department of Mathematics, Consultant, Agriculture, Yarrowia

COPENHAGEN, Denmark, March 9, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces that it has accepted a new project into its Bio Studio program to develop an engineered mycoprotein meat alternative.

Key Points: 
  • COPENHAGEN, Denmark, March 9, 2023 /PRNewswire/ -- BioInnovation Institute (BII), an international non-profit foundation, incubating and accelerating world-class life science research, today announces that it has accepted a new project into its Bio Studio program to develop an engineered mycoprotein meat alternative.
  • BII's Bio Studio program supports world-leading entrepreneurial Principal Investigators (PIs) who want to translate their innovative research ideas into new solutions to the benefit of planetary and human health.
  • Thus, the goal of this project is to create an initial minimum viable product (MVP) of a holistically engineered mycoprotein meat alternative.
  • The Bio Studio program is a recently established BII program with the ambition to build and run a leading life science company creation facility in Europe.

AION Labs Launches AI Startup for De Novo Antibody Design

Retrieved on: 
Tuesday, February 28, 2023
Transfer, Biotechnology, Safety, Molecular biology, Doctor of Philosophy, Merck, MD, Intelligence, Artificial intelligence, De novo, Amazon Web Services, BioMed Central, Biomedical data science, Biophysics, AWS, Drug discovery, Research, Kinetics, Algorithm, Patient, AION, AI, Israel Innovation Authority, Probability, European Molecular Biology Laboratory, European, AstraZeneca, Immunization, Virology, Machine learning, Antibody, EMBL, Health, Pharmaceutical industry, Vaccine, Medical device, Fine chemical, Pfizer, Teva

REHOVOT, Israel, Feb. 28, 2023 /PRNewswire/ --  AION Labs, the first-of-its-kind innovation lab spearheading the adoption of AI technologies and computational science to solve therapeutic challenges, announced today the formation of DenovAI, the lab's second startup approved by the Israel Innovation Authority. The new company will develop an AI-powered biophysics solution that can discover potential antibodies completely de novo (from scratch), and then suggest candidates likely to make effective drugs.

Key Points: 
  • DenovAI aims to build a next-generation computational platform for the de novo design of strongly binding antibodies directed towards epitopes[1] of choice.
  • In addition to funding, support and mentorship, AION Labs and its pharma partners will provide DenovAI with pharmaceutical data for model training and advanced machine learning development.
  • "We are developing an end-to-end AI framework that can predict antibody sequences and structures that bind with high affinity and selectivity to any given epitope.
  • "Sitting at the intersection between biophysics, biotechnology and AI, DenovAI has the potential to drive innovation in drug discovery, coupled with AION Labs strong resources and experience.

Paul Flicek, D.Sc. joins JAX as inaugural chief data science officer to build global data science initiative

Retrieved on: 
Wednesday, February 8, 2023
Jackson Laboratory, EMBL, Master of Science, Fellow of the Academy of Medical Sciences, JAX, Drake University, Data science, ENCODE, EMBL-EBI, Biomedical engineering, Computational biology, University, Research, Reference genome, Genetics, European Molecular Biology Laboratory, Laboratory, Physics, International, International Human Epigenome Consortium, Partnership, BAR, Genomics, Faculty, European Bioinformatics Institute, European, Ensembl genome database project, Washington University in St. Louis, Management, Science

BAR HARBOR, Maine, Feb. 8, 2023 /PRNewswire/ -- The Jackson Laboratory (JAX) has appointed world-class data scientist Paul Flicek, D.Sc., as its inaugural chief data science officer (CDSO).

Key Points: 
  • BAR HARBOR, Maine, Feb. 8, 2023 /PRNewswire/ -- The Jackson Laboratory (JAX) has appointed world-class data scientist Paul Flicek, D.Sc., as its inaugural chief data science officer (CDSO).
  • In this new leadership role, Flicek will be responsible for building and executing a comprehensive data science strategy across JAX.
  • "Dr. Flicek's contributions to open genomic resources have had a substantial impact on the global scientific community," said JAX President and CEO Lon Cardon , Ph.D., FMedSci.
  • Flicek will create new data science capabilities for JAX by envisioning and executing strategies to enhance the research and discovery enterprise and building a robust team of data scientists.